• COVID-19
• Other research productsclose
• 2014-2023close
• Other ORP type close

Noticia publicada en la Web del ISCIII 21/10/2021 Nota de prensa sobre Los datos de la 8ª ronda de la encuesta COSMO-Spain de percepción social de la pandemia confirman el aumento en la confianza en las vacunas, con un nuevo máximo; el 89% de las personas encuestadas se pondría una dosis adicional si las autoridades lo recomendasen. Desciende la preocupación por el SARS-Cov-2 y la COVID-19, crece el optimismo sobre las perspectivas de la pandemia, se reduce la búsqueda de información y la comunidad científica sigue siendo el colectivo que más confianza genera. No

Las enfermedades neurodegenerativas son dolencias que afectan principalmente a las neuronas del cerebro. La más común es la enfermedad de Alzheimer, seguida de la enfermedad de Parkinson, la demencia senil y los accidentes cerebrovasculares. El objetivo principal del trabajo es comprobar si la COVID afecta de alguna forma a estas enfermedades. El presente trabajo ha contado con la colaboración del Dr. Alberto Rábano, patólogo dela fundación Cien y director de tejidos. Según sus observaciones, la COVID está afectando al Sistema Nervioso Central (SNC), con manifestaciones como encefalitis que derivan en ictus; los cuales, a su vez, están asociados a graves secuelas funcionales. Tanto las observaciones del Dr. Rábano como los resultados de la encuesta realizada para este proyecto, revelan que las enfermedades neurodegenerativas no están empeorando por la COVID. Pero esta infección se asocia a mayor riesgo de ictus lo que traerá consecuencias a futuro, aunque aún es pronto para asentar estas observaciones. Según las declaraciones del Dr. Rábano, el factor de riesgo para la enfermedad del Alzheimer es el gen APOE 4, y que a su vez es un factor de riesgo para la COVID; las personas que tienen esta forma del gen, han tenido los síntomas más graves. Según estudios realizados a un grupo de personas, aquellos que tenían esta variante genética dieron positivo en COVID-19 lo que sugiere que el riesgo se duplica. Además, la COVID está causando una serie de daños que van a propiciar la aparición del Alzheimer; a su vez el aislamiento y el confinamiento ha afectado negativamente a las personas que presentan estas enfermedades. Técnico Superior en Anatomía Patológica y Citodiagnóstico Universidad Europea de Madrid Presencial

Aprovat per Decret de l'Alcaldia de 03-12-2020 Document prepared in the context of deconfinement to the emergency caused by COVID-19. Document elaborat en el context de desconfinament davant l’emergència provocada per la COVID-19. Documento elaborado en el contexto de desconfinamiento ante la emergencia provocada por la COVID-19. Annex I. Noves clàusules d'igualtat i retribució per objectius Annex II. Nou protocol i redacció de la condició d'execució SOC03.08. Conciliació responsable del temps laboral, familiar i personal Annex III. Compliance penal i obligacions en matèria d'integritat i els conflictes d'interès

The majority of women in Mexican cities depend on public transport to get to work. Yet sprawling urban development and a lack of safe, well-connected transport infrastructure means that they are denied mobility and the opportunities that come with it. Mexico’s government must look at transport through a gender lens as the country emerges from the COVID-19 crisis, write Catarina Heeckt (LSE Cities) and Ana María Martínez (WRI Cities).

The Covid-19 pandemic is a global crisis, yet it has largely been managed by states acting independently. Arvind Ashta argues that in light of the pandemic, we should seriously consider the potential advantages of moving toward a world federal government. In a previous EUROPP article written during the first wave of the pandemic in Europe, ... Continued

Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Professionals; Atenció primària Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Profesionales; Atención primaria Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Professionals; Primary care Fullet adreçat als professionals sanitaris d'atenció primària amb preguntes i respostes sobre com convé actuar enfront el coronavirus COVID-19.

The world is currently embroiled in a pandemic of coronavirus disease 2019 (COVID-19), a respiratory illness caused by the novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity of COVID-19 disease ranges from asymptomatic to fatal acute respiratory distress syndrome. In few patients, the disease undergoes phenotypic differentiation between 7 and 14 days of acute illness, either resulting in full recovery or symptom escalation. However, the mechanism of such variation is not clear, but the facts suggest that patient's immune status, comorbidities, and the systemic effects of the viral infection (potentially depending on the SARS-CoV-2 strain involved) play a key role. Subsequently, patients with the most severe symptoms tend to have poor outcomes, manifest severe hypoxia, and possess elevated levels of pro-inflammatory cytokines (including IL-1β, IL-6, IFN-γ, and TNF-α) along with elevated levels of the anti-inflammatory cytokine IL-10, marked lymphopenia, and elevated neutrophil-to-lymphocyte ratios. Based on the available evidence, we propose a mechanism wherein SARS-CoV-2 infection induces direct organ damage while also fueling an IL-6-mediated cytokine release syndrome (CRS) and hypoxia, resulting in escalating systemic inflammation, multi-organ damage, and end-organ failure. Elevated IL-6 and hypoxia together predisposes patients to pulmonary hypertension, and the presence of asymptomatic hypoxia in COVID-19 further compounds this problem. Due to the similar downstream mediators, we discuss the potential synergistic effects and systemic ramifications of SARS-CoV-2 and influenza virus during co-infection, a phenomenon we have termed "COVI-Flu." Additionally, the differences between CRS and cytokine storm are highlighted. Finally, novel management approaches, clinical trials, and therapeutic strategies toward both SARS-CoV-2 and COVI-Flu infection are discussed, highlighting host response optimization and systemic inflammation reduction.

As Empresas Familiares são uma forma única e particular de organização profundamente interessante devido ao seu próprio estilo de modelo de negócios, diferenças hierárquicas, valores e princípios. Consequentemente, a sua capacidade de inovar difere de outras formas de organização. Com a chegada da pandemia COVID-19, os modelos de negócios tiveram que atualizar as suas abordagens, inovando e agindo de acordo com os hábitos de consumo e restrições sanitárias. Mundialmente, algumas empresas tiveram que mudar, tendo na sua centralidade abordagens e mentalidades inovadoras, enquanto outras não conseguiram colocar esses mesmos mecanismos em ação. Esta dissertação e pesquisa tem como objetivo primordial analisar a capacidade de inovação das empresas familiares no que diz respeito à interação com o cliente e como a pandemia desequilibra o seu modelo. Além disso, com este estudo, espera-se que alguns resultados possam orientar outras empresas familiares sobre como enfrentar e interagir com algumas barreiras inovadoras e dar-lhes a capacidade de lidar com as mesmas. Family Businesses are a particular and unique form of organization deeply interesting due to their own business model style, hierarchical differences, values and principles. Consequently, their capacity to innovative differ from other types of organization. With the arrival of COVID-19 Pandemic, business models had to adapt their innovative approaches to act accordingly with consumer habits and sanitary restrictions. Worldwide, some businesses had to change, with innovative approaches and mindsets, while other could not bring those same mechanisms to action. This dissertation aims to analyze the capacity of family entities to innovation regarding their customer interaction and how the pandemic imbalance their model. Also, with this study, it is expected that some results might guide other family firms on how to deal and interact with the barriers and to give the capacity to deal with the same barriers.